New drug combo shows promise for tough head and neck cancers

NCT ID NCT06919666

Ongoing Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This early-phase trial tests a new drug called NT219 combined with either pembrolizumab or cetuximab in 29 adults with head and neck cancer that has returned or spread. The goal is to see if the combination shrinks tumors. Participants receive weekly NT219 plus one of the other drugs until the cancer worsens or side effects become too severe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NT219 (a small molecule drug) combined with either pembrolizumab or cetuximab
What this could lead to: If successful, this could point toward a new treatment option for people with head and neck cancer that has come back or spread.
What could go wrong: This is an early-phase trial with only 29 participants, so results may not apply to everyone. The drug combination may cause side effects or not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK CANCER HEAD AND NECK SQUAMOUS CELL CARCINOMA

Contacts and locations

Locations

UCHealth Highlands Ranch Hospital

Highlands Ranch, Colorado, 80126, United States
Universtiy of Colorado Hospital

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.